期刊文献+

磁性氧化铁纳米颗粒的生物相容性研究进展 被引量:10

Research progress in biocompatibility of magnetic iron oxide nanoparticles
原文传递
导出
摘要 磁性氧化铁纳米颗粒的生物相容性是其应用于临床研究的前提之一.生物相容性一般是指材料与宿主之间的相容性,包括组织相容性和血液相容性.目前认为,对生物材料的生物相容性研究与评价应从整体、细胞和分子这3个水平全方位进行.本文主要将近期通过细胞、分子和整体水平相关试验进行的磁性氧化铁纳米颗粒生物相容性评价工作的进展及其研究中存在的问题作一综述. Biocompatibility of magnetic iron oxide nanoparticles is one of the preconditions for clinical research.Generally,biocompatibility implies compatibility between materials and living hosts,including tissue and blood compatibility.At present,methods for evaluating biocompatibility must be implemented via three omni-directional levels:integrated,cellular and molecular.This article mainly reviews the recent research concerned with biocompatibility of magnetic iron oxide nanoparticles through the three omni-directional levels.Unresolved problems in evaluation of magnetic iron oxide nanoparticles are also covered.
出处 《科学通报》 EI CAS CSCD 北大核心 2011年第26期2223-2228,共6页 Chinese Science Bulletin
基金 国家自然科学基金(51103049,81171471,31170939) 福建省自然科学基金(2010J05027,2011501223)资助项目
关键词 磁性氧化铁 纳米颗粒 生物相容性 RT-PCR 胞质分裂阻滞 微核试验 magnetic iron oxide nanoparticles biocompatibility RT-PCR cytokinesis block micronucleus
  • 相关文献

参考文献47

  • 1Widder K J, Senyei A E, Ranney D F. In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Res, 1980, 40:3512-3517.
  • 2Evanochko W T, Ng T C, Glickson J D. Application of in vivo NMR spectroscopy to cancer. Magn Reson Med, 1984, 1 : 508-534.
  • 3Harisinghani M G, Barentsz J, Hahn P F, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med, 2003, 348:2491-2499.
  • 4武新英,张景峰,林冰影,张敏鸣.RGD标记纳米氧化铁的肿瘤血管生成分子影像学研究[J].科学通报,2010,55(19):1891-1899. 被引量:7
  • 5杨芳,李熠鑫,陈忠平,顾宁.超声、磁共振多功能微气泡造影剂的制备和应用[J].科学通报,2009,54(9):1181-1186. 被引量:10
  • 6Baselt D R, Lee G U, Natesan M, et al. A biosensor based on magnetoresistance technology. Biosens Bioelectron, 1998, 13:731-739.
  • 7Gu H W, Xu K M, Xu C J, et al. Biofunctional magnetic nanoparticles for protein separation and pathogen detection. Chem Commun, 2006, 941-949.
  • 8Lewin M, Carlesso N, Tung C H, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol, 2000, 18:410-414.
  • 9杨晓芳,奚廷斐.生物材料生物相容性评价研究进展[J].生物医学工程学杂志,2001,18(1):123-128. 被引量:108
  • 10ISO 10993-1: 1992. Biological evaluation of medical devices-Part 1: Evaluation and testing.

二级参考文献64

  • 1Jiang, Hui-Jie,Zhang, Zai-Ren,Shen, Bao-Zhong,Wan, Yong,Guo, Hong,Li, Jin-Ping.Quantification of angiogenesis by CT perfusion imaging in liver tumor of rabbit[J].Hepatobiliary & Pancreatic Diseases International,2009,8(2):168-173. 被引量:21
  • 2吕晓迎.牙科材料细胞毒性评定的新方法(MTT试验)[J].中华口腔医学杂志,1995,30(6):377-379. 被引量:101
  • 3肖苏尧,童春义,刘选明,俞丹密,刘巧玲,薛昌刚,唐冬英,赵李剑.肿瘤靶向性药物载体叶酸-淀粉纳米颗粒的研制与应用[J].科学通报,2006,51(10):1151-1155. 被引量:16
  • 4Schutt E G, Klein D H, Mattrey R M, et al. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: The key role of perfluorochemicals. Angew Chem Int Ed, 2003, 42:3218-3235
  • 5Lencioni R. Impact of european federation of societies for ultrasound in medicine and biology (EFSUMB) guidelines on the use of contrast agents in liver ultrasound. Eur Radiol, 2006, 16:1610-1613
  • 6tride E, Edirisin~he M. Novel microbubble preparation technologies. Soft Matter, 2008, 4:2350-2359
  • 7Correas J M, Bridal L, Lesavre A, et al. Ultrasound contrast agents: Properties, principles of action, tolerance, and artifacts. Eur Radiol, 2001, 11:1316-1328
  • 8Cosgrove D. Ultrasound contrast agents: An overview. Eur J Radiol, 2006, 60:324-330
  • 9Leen E, Moug S J, Horgan P. Potential impact and utilization of ultrasound contrast media. Eur Radiol, 2004, 14(suppl8): 16-24
  • 10Miller D L, Averkiou M A, Brayman A A, et al. Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultras Med, 2008, 27(4): 611-632

共引文献143

同被引文献107

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部